Maquet Medical Systems USA Announces Exclusive U.S. Distribution Agreement With ReFlow Medical, Inc. To Expand Cardiac Solutions


December 15, 2015 - Wayne, NJ- Maquet Medical Systems USA announced today an exclusive U.S. distribution agreement with ReFlow Medical, Inc., a company focused on developing technologies for accessing and treating cardiovascular disease, to distribute their complete line of catheters. The agreement includes the Wingman Crossing Catheters (Wingman14, Wingman18, Wingman35) and the speX™ Shapeable Support Catheter, which are cleared for use in conjunction with steerable guidewires to access discrete regions of the peripheral vasculature.  It may be used to facilitate placement and exchange of guidewires and other interventional devices and provide a conduit for the delivery of saline solutions or diagnostic/therapeutic agents.

“We’ve partnered with ReFlow Medical on this distribution agreement as their innovative catheters greatly enhance our current offerings to the physicians that we serve every day,” said Raoul Quintero, President and CEO North America, Maquet Medical Systems USA. “We look forward to working with ReFlow Medical to better address the unmet needs and clinical challenges that interventionalists and their teams face in treating their patients with peripheral blockages.”

The Wingman Crossing Catheter with its unique extendable bevel tip is used in conjunction with steerable guidewires of the physician’s choice to access discrete regions of the peripheral vasculature and enable rapid, routine, off-the-shelf lesion crossing. The speX Shapeable Support Catheter with its shapeable tip option is the only support catheter that retains its shape and allows physicians to reshape as needed in order to rapidly adjust to the specific needs of each case and each patient.

"We are very excited to partner with Maquet and form an alliance with such a renowned and well-respected medical device company,” said Isa Rizk, CEO and Co-Founder of ReFlow Medical. "We look forward to working with Maquet’s extensive sales and marketing team to drive market adoption of this unique and highly differentiated product line. We share Maquet's goals of improving patient outcomes and reducing hospital costs with highly innovative novel medical device technologies, and look forward to a mutually beneficial relationship.”

Maquet will begin distributing the products during the first quarter of 2016.

About Maquet
Maquet, a trusted partner for hospitals and physicians for more than 175 years, is a global leader in medical systems. The company offers innovative therapy solutions and infrastructure capabilities for high-acuity areas within the hospital - including the operating room (OR), hybrid OR/cath lab, and intensive care unit (ICU) - as well as intra- and inter-hospital patient transport. Additionally, Maquet develops intelligent and sustainable room concepts that exceed the expectations of modern hospitals, working in close cooperation with customers, production engineers and architects to integrate high quality products and services.
Headquartered in Rastatt, Germany, Maquet is the largest subsidiary of the publicly listed Getinge Group AB of Sweden. Maquet generated about 1.55 billion Euros in 2014, representing more than half of the Getinge Group's annual revenue of 2.93 billion Euros. Maquet has 7,000 employees and provides 53 international sales and service organizations, as well as a network of more than 300 sales partners. For more information, please visit

About Getinge
Getinge is a globally leading medical technology company that operates in the areas of surgery, intensive care, infection control, care ergonomics and wound care. Getinge has nearly 16,000 employees in over 40 countries and generates sales of about SEK 27 billion (2014). The Group is divided into three business areas: Medical Systems, Extended Care and Infection Control, and operates under the brands of Maquet, ArjoHuntleigh and Getinge.

About ReFlow Medical, Inc.
ReFlow Medical, Inc. is a private company focused on empowering physicians through the design and development of innovative and cost-effective technologies for cardiovascular disease. ReFlow is developing a family of products to treat chronic total occlusions in the peripheral and coronary vasculature.

For more information, please visit